High expression of two genes selected by iAFLP: a new prognostic factor of estrogen receptor-positive breast cancer.
To detect patients with poor prognosis among those with estrogen receptor (ER)-positive breast cancer, who generally show good prognosis, we analyzed gene expression profiles of 35 ER-positive tumors by using a high through-put RT-PCR technique, iAFLP. High expression of six genes out of 7,508 was related to poor prognosis in this group. From these six genes, NFE2L2 and TIAL1 were selected as genes associated with poor prognosis by means of a validation study with another set of 56 ER-positive breast cancers. High expression of these two genes was determined to be significantly predictive for poor prognosis of patients with ER-positive breast cancer, and may help to achieve optimal selection of adjuvant treatment for such patients.
Aritake
Noriko
N
Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Tamaki
Yasuhiro
Y
Masuda
Norikazu
N
Nakano
Yoshiaki
Y
Monden
Takushi
T
Noguchi
Shinzaburo
S
Monden
Morito
M
D000328:Adult; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D017931:DNA Primers / Q000737:chemistry; D018076:DNA, Complementary / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D005786:Gene Expression Regulation; D015972:Gene Expression Regulation, Neoplastic; D005821:Genetic Techniques; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009362:Neoplasm Metastasis; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism*; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D016896:Treatment Outcome
D017931:DNA Primers; D018076:DNA, Complementary; D011960:Receptors, Estrogen